|
AU2013204153A1
|
|
Treatment of TNFalpha related disorders
|
|
AU2013203670A1
|
|
Automatic injection device
|
|
AU2013202859A1
|
|
Crystalline anti-hTNFalpha antibodies
|
|
WO2013055828A1
|
|
Managing healthcare services
|
|
CA2789168A1
|
|
Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
|
|
MX2012007042A
|
|
Improved firing button for automatic injection device.
|
|
KR20120038406A
|
|
Stable high protein concentration formulations of human anti-tnf-alpha antibodies
|
|
WO2009118662A2
|
|
Methods and compositions for treating bone loss
|
|
CA2710333A1
|
|
Predicting long-term efficacy of a compound in the treatment of psoriasis
|
|
CN101802005A
|
|
Compositions and methods comprising binding proteins for adalimumab
|
|
CN101848733A
|
|
The method and composition that is used for pulmonary administration TNF alpha inhibitor
|
|
WO2008154543A2
|
|
Methods for treating juvenile idiopathic arthritis
|
|
WO2008150490A2
|
|
Uses and compositions for treatment of psoriasis and crohn's disease
|
|
KR20090025305A
|
|
Automatic injection device
|
|
RU2438721C2
|
|
Automatic injection device
|
|
WO2007120823A2
|
|
Uses and compositions for treatment of psoriasis
|
|
EP2007426A2
|
|
Uses and compositions for treatment of psoriatic arthritis
|
|
WO2007120626A2
|
|
Uses and compositions for treatment of ankylosing spondylitis
|
|
EP2010214A2
|
|
Uses and compositions for treatment of rheumatoid arthritis
|
|
EP2010213A2
|
|
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
